Last reviewed · How we verify
Intrarosa — Competitive Intelligence Brief
marketed
Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Intrarosa (Intrarosa) — Center for Vulvovaginal Disorders.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intrarosa TARGET | Intrarosa | Center for Vulvovaginal Disorders | marketed | Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase | ||
| Dehydroepiandrosterone | Dehydroepiandrosterone | National Institute of Dental and Craniofacial Research (NIDCR) | marketed | Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Intrarosa — Competitive Intelligence Brief. https://druglandscape.com/ci/intrarosa. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab